18th June 2021
- 0 comments
Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, has raised $9.6M seed financing led by Khosla Ventures, with participation from Backed VC, Apollo Health Ventures, Selvedge, Hoxton and Hermes-Epitek. The funding will be used to advance the development of Ochre Bio’s RNA therapies and expand their deep phenotyping platform to identify and validate new liver targets.
...In order to read the full story we need you to be registered with us, please click the links below to login or register.